A World Health Organization conference to be held in Geneva, Switzerland this month may form policy for the regulation of cannabidiol (CBD) around the globe.
The conference, a gathering of the knowledgeable Committee on Drug Dependence (ECDD), is being held, November 6-10, 2017, and will debate seventeen mind-expanding substances, together with CBD. The substances are going to be reviewed for its potential for dependence, abuse and harm to health. The ECDD will then make recommendations to the international organization Secretary-General on the need and degree of potential regulation for the medicine. The ECDD meets annually to judge the dependence-producing properties and harm to the health of mind-expanding substances, together with those with medicative uses.
Raúl Elizalde, the president of the medical marijuana company HempMeds Mexico, has been invited to talk concerning CBD at the meeting. Elizalde has been an outspoken advocate for the meditative use of cannabis since he began using CBD to assist his 10-year-old girl, Grace, who suffers from a severe type of brain disorder.
Raúl Elizalde was instrumental within the group action of medical cannabis in Mexico, and his company produces the only cannabis drugs presently allowed by the Mexican government. Elizalde plans to urge the delegates to not advocate the regulation of CBD. “I’m excited to talk with world leaders and urge them to not think that CBD is psychoactive and not schedule it as a drug,” he said. Elizalde fears that a recommendation to regulate CBD can limit its use to the pharmaceutical trade and deny access to incalculable patients who already have faith in it. Instead, Elizalde believes that CBD should be classified as a dietary supplement. “I hope [they] can contemplate CBD to be similar to vitamin C, a supplement that contains a suggested daily dose—not a drug that then needs to be regulated,” he said.
The decisions of the ECDD may have wide-reaching implications. A 1971 United Nations treaty called the Convention on Hallucinogenic Substances specifies that substances ought to be regulated by member nations, together with the United States. A determination by the international organization that CBD shouldn’t be subject to regulation may spur its rescheduling underneath the Controlled Substances Act. CBD continues to be listed as a Schedule One narcotic, despite a 2004 U.S. Ninth Circuit Court of Appeals ruling that non-psychoactive constituents of hemp don’t seem to be subject to regulation underneath the law.
Share this Post